US › Healthcare

Filana Therapeutics, Inc. (FLNA)

US · Healthcare · Biotechnology

$1.00-3.26%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-10.3M

Profit YoY

+55.9%

EPS

$-0.18

EPS estimate

$-0.21

EPS came in at -0.18 against a street estimate of -0.21 — a beat of 14.3%.

Key statistics

Market cap

$42.0M

Forward P/E

151.5

P/B

0.63

Book value

$1.41

EPS (TTM)

$-1.58

52-week high

$4.98

52-week low

$0.86

50-day MA

$1.22

200-day MA

$2.07

Beta

-0.74

Analyst view

with an average price target of $6.50.

Shareholding

Insiders

2.05%

Institutions

28.55%

Largest institutional holders

Fund	Stake
Vanguard Group Inc	4.92%
Marshall Wace Asset Management Ltd	4.17%
Two Sigma Investments LLC	4.12%
Vanguard Capital Management, LLC	4.00%
BlackRock Inc	2.93%
Two Sigma Advisers, LLC	1.98%
Geode Capital Management, LLC	1.23%
D. E. Shaw & Co LP	1.16%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Filana Therapeutics, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.